Table 4.
Multivariable analysis of prognostic factors in locally advanced head and neck squamous cell carcinoma
| Endpoint | HR (95% CI) | P value |
|---|---|---|
| Disease-free survival | ||
| Sex | 0.357 (0.145–0.880) | 0.025 |
| Age | 1.209 (0.717–2.037) | 0.477 |
| T stage | 0.300 (0.141–0.637) | 0.002 |
| N stage | 0.435 (0.196–0.964) | 0.040 |
| Karnofsky scale | 0.408 (0.191–0.874) | 0.021 |
| HPV status | 0.923 (0.282–3.019) | 0.894 |
| Primary tumor site | 1.265 (0.708–2.258) | 0.427 |
| DWI-guided dose painting | 0.559 (0.324–0.966) | 0.037 |
| Local recurrence-free survival | ||
| Sex | 0.412 (0.156–1.088) | 0.073 |
| Age | 1.280 (0.752–2.179) | 0.364 |
| T stage | 0.310 (0.146–0.660) | 0.002 |
| N stage | 0.457 (0.206–1.015) | 0.054 |
| Karnofsky scale | 0.378 (0.175–0.814) | 0.013 |
| HPV status | 0.877 (0.267–2.878) | 0.829 |
| Primary tumor site | 1.186 (0.661–2.127) | 0.568 |
| DWI-guided dose painting | 0.568 (0.328–0.984) | 0.044 |
| Regional recurrence-free survival | ||
| Sex | 3.344 (1.361–8.214) | 0.006 |
| Age | 1.152 (0.640–2.075) | 0.637 |
| T stage | 0.175 (0.062–0.491) | < 0.001 |
| N stage | 0.544 (0.242–1.223) | 0.141 |
| Karnofsky scale | 0.505 (0.212–1.200) | 0.122 |
| HPV status | 2. 334 (0.316–17.245) | 0.406 |
| Primary tumor site | 1.217 (0.636–2.328) | 0.553 |
| DWI-guided dose painting | 0.684 (0.378–1.238) | 0.209 |
| Locoregional recurrence-free survival | ||
| Sex | 0.331 (0.134–0.817) | 0.017 |
| Age | 1.236 (0.731–2.089) | 0.429 |
| T stage | 0.306 (0.144–0.650) | 0.002 |
| N stage | 0.446 (0.201–0.988) | 0.047 |
| Karnofsky scale | 0.394 (0.183–0.846) | 0.017 |
| HPV status | 0.878 (0.268–2.877) | 0.829 |
| Primary tumor site | 1.260 (0.704–2.256) | 0.437 |
| DWI-guided dose painting | 0.558 (0.322–0.968) | 0.038 |
| Distant metastasis-free survival | ||
| Sex | 0.343 (0.129–0.916) | 0.033 |
| Age | 1.372 (0.760–2.478) | 0.294 |
| T stage | 0.307 (0.137–0.690) | 0.004 |
| N stage | 0.450 (0.190–1.068) | 0.070 |
| Karnofsky scale | 0.417 (0.182–0.955) | 0.038 |
| HPV status | 1.066 (0.250–4.538) | 0.931 |
| Primary tumor site | 1.208 (0.641–2.275) | 0.559 |
| DWI-guided dose painting | 0.536 (0.293–0.979) | 0.043 |
| Overall survival | ||
| Sex | 0.525 (0.154–1.789) | 0.303 |
| Age | 1.591 (0.785–3.223) | 0.197 |
| T stage | 0.183 (0.055–0.606) | 0.005 |
| N stage | 0.540 (0.206–1.414) | 0.210 |
| Karnofsky scale | 0.398 (0.160–0.987) | 0.047 |
| HPV status | 1.803 (0.239–13.598) | 0.567 |
| Primary tumor site | 1.140 (0.533–2.441) | 0.736 |
| DWI-guided dose painting | 0.885 (0.449–1.746) | 0.725 |
Abbreviation: HPV = Human Papillomavirus; HR = hazard ratio; IC = induction chemotherapy;